Company Description
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders.
It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
The company’s ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential.
It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex.
Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
| Country | United States |
| Founded | 2003 |
| IPO Date | Jul 31, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 166 |
| CEO | Scott Braunstein |
Contact Details
Address: 5 Radnor Corporate Center, Suite 500 Radnor, Pennsylvania 19087 United States | |
| Phone | 484 801 4670 |
| Website | marinuspharma.com |
Stock Details
| Ticker Symbol | MRNS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001267813 |
| CUSIP Number | 56854Q200 |
| ISIN Number | US56854Q2003 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Scott Braunstein | Chief Executive Officer |
| Steven Pfanstiel | Chief Financial Officer |
| Steven Pfanstiel | Chief Operating Officer |
| Sonya Weigle | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Feb 11, 2025 | SCHEDULE 13G | Filing |
| Feb 11, 2025 | SCHEDULE 13G/A | Filing |
| Feb 11, 2025 | SCHEDULE 13G/A | Filing |
| Feb 11, 2025 | 25-NSE | Filing |
| Feb 11, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 11, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 11, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 11, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 11, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |